TERMS OF REFERENCE
Assess the scientific and strategic value of applications for research activities seeking financial support from the Trust including but not limited to:
Internal Funding Applications (Items of expenditure > £10,000 to be brought to RDDC)
Pump Priming Applications
Research Fellow Funds
Research Champion Consultant level appointments
Point of contact and decision making re NIHR and UKCRN networks
Identification and targeted dissemination of portfolio and non-portfolio research funding opportunities
Oversight of: R&D Institute including statistics, Tissue Bank, Intellectual Property including external consultancy, CTBI Building and its function
Support for Library & Knowledge Services, where appropriate
Leadership, in conjunction with the University, of the development of the Heart and Lung Research Institute.
Roles of Members
In addition all Clinical Groups will be expected to have:
i R&D as a standing item on their agenda
ii A designated Research Officer from the RDD committee who will attend relevant meetings.
2 Clinical Group representatives will be expected to:
i Undertake dual representation i.e. representation of all of their clinical group constituents on the RDD and of the RDD on their clinical group
ii Promote and champion R&D at their clinical/business unit meetings
iii Conduct (or arrange the conduct of) clinical peer review of new projects
This Directorate model will enable new projects to be properly assessed alongside any service requirements that are needed for their introduction.
Any conflicts that arise will be dealt with by the RDD committee.
Core Members / Representatives: Clinical Director of R&D (Chair), Senior R&D Manager
Clinical Group/Business Unit Representatives: Cardiology, Pathology,Radiology, Research Campion, Secretarial Support, Statistician, Surgery, Theatres, Critical Care and Anaesthetics, Thoracic Medicine, Tissue Bank, Transplant, University of Cambridge.
Other Attendees:Education (inc. External),Finance,Library Services,Nursing and Professions Allied to Medicine,Pharmacy,R&D Admin & Finance Manager
Observers from within the R&D Department are welcome with prior discussion with the Senior R&D Manager or the Clinical Director.
Core members will observe an RDD meeting attendance policy. Attendance at 10 meetings per year is the expected minimum standard. Failure to attend 2 consecutive meetings (with failure to provide a deputy) will trigger a letter from the Chair.
The RDD Comprises
|Dr Ian Smith (Chair)||Clinical Director, R&D|
|Mr Yasir Abu-Omar||Consultant Surgeon & R&D Representative for Surgery|
|Dr Bobby Agrawal||Consultant Radiologist & R&D Representative for Radiology|
|Prof. Martin Bennett||BHF Professor of Cardiovascular Sciences, University of Cambridge|
|Library and Knowledge Services Manager|
|Dr Martin Goddard||Clinical Lead for Tissue Bank|
|Dr Jules Hernandez-Sanchez||Statistician|
Dr Stephen Hoole
|Consultant Cardiologist & R&D Representative for Tissue Bank|
|Dr Vicky Hughes||Senior R&D Manager|
|Sophie Jackson||Research Manager|
|Dr Clive Lewis||Lead for External Education|
|Prof Nick Morrell||Professor of Cardiopulmonary Medicine, University of Cambridge|
|Dr Jas Parmar||Consultant Physician & R&D Representative for Cardiothoracic Transplantation|
|Dr Doris Rassl||Consultant Histopathologist & R&D Representative for Tissue Bank|
|Dr Robert Rintoul||Consultant Respiratory Physician & R&D Representative for Thoracic Medicine|
|Jane Elliott||Nursing Directorate|
|Dr Kiran Salaunkey||Consultant Anaesthetist|
|Rosie Thornton||Finance Manager|
|Dr Mark Toshner||Consultant Respiratory Physician & 'Research Champion'|
|Dr Nick West||Consultant Cardiologist|
The Directorate shall be deemed quorate if there is representation of:
Director of R&D (or deputy)
R&D Directorate representative
Four representatives from clinical groups/business units.
Dates of Meetings
Meetings are held every month, on the second Friday of the month, and will commence promptly at 8.00am. Duration of the meetings will be up to two hours depending on the agenda.
The RDD committee meeting agenda will be determined primarily by the Director of R&D and the Senior R&D Manager, and will be circulated together with briefing papers a minimum of three working days prior to the next meeting to enable sufficient time for Directorate Members to give them due consideration. .
A detailed Action List summarising all actions will be produced and distributed to Directorate members within 5 working days of the meeting. Minutes of Directorate meeting will be formally recorded and distributed to Directorate Members prior to the next meeting.
Circulation of Minutes
Members of the Research & Development Directorate, Chief Executive, Medical Director and Research Officers.